Meeting
2020 ASCO-SITC Clinical Immuno-Oncology Symposium
A real-world analysis of non-small cell lung cancer patients treated with pembrolizumab or pembrolizumab in combination with pemetrexed and platinum.
Authors
Himani Agg
Eli Lilly and Company, Indianapolis, IN
Himani Agg, Katherine B. Winfree, Yajun Emily Zhu, Catherine Muehlenbein
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Poster Session B
Track
Breast and Gynecologic Cancers,Developmental Therapeutics,Genitourinary Cancer,Head and Neck Cancer,Lung Cancer,Melanoma/Skin Cancers,Gastrointestinal Cancer,Combination Studies,Implications for Patients and Society,Miscellaneous Cancers,Hematologic Malignancies
Sub Track
Immune Checkpoints and Stimulatory Receptors
Citation
J Clin Oncol 38, 2020 (suppl 5; abstr 53)
Abstract #
53
Poster Bd #
C2
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Annual Meeting
Treatment patterns and unmet need for patients with advanced non-small cell lung cancer and poor performance status: A real-world evidence study.
First Author: Stephen V. Liu
Poster
2023 ASCO Annual Meeting
Real-world study of treatment patterns and clinical outcomes in patients with metastatic non-small cell lung cancer (mNSCLC) post-approval of immunotherapy in the community oncology setting.
First Author: Alexander I. Spira
Poster
2023 ASCO Genitourinary Cancers Symposium
US real-world first-line (1L) treatment patterns and outcomes for patients with metastatic urothelial carcinoma (mUC) following maintenance avelumab approval.
First Author: Haojie Li
Poster
2022 ASCO Annual Meeting
The Selective Personalized Radio-immunotherapy for Locally Advanced NSCLC Trial (SPRINT): Initial results.
First Author: Nitin Ohri